



DexTech

Know-how in Translational Research

Pressmeddelande 2018-10-04

DexTech Medical AB, 556664-6203

First result from DexTechs phase IIb-study on OsteoDex

OsteoDex, the company's phase 2b-project for treatment of advanced prostate cancer, castration resistant prostate cancer (CRPC), is finished and the first results can be reported. The study has the title "A randomized, double-blind, dose-finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration-resistant prostate cancer (CRPC) and skeletal metastases" and is conducted in Sweden (Norrlands Universitetssjukhus, Umeå, Södersjukhuset, Stockholm, Universitetssjukhuset, Örebro), in Finland (Tampere University Hospital), in Estonia (East Tallin Central Hospital, Tartu University Hospital) and in Latvia (Riga East University Hospital, Daugavpils Regional Hospital).

Fifty one percent of the patients completed full treatment (5 months, dose 2ggr/month). Of these, 56 % had stable disease (improved/stable) regarding their bone metastasis. Concerning marker for bone resorption, 68 % showed declining values with more than 50 %. Other bone markers declined with 43 % - 71 % compared to base line. The data indicate a powerful inhibition of the vicious cycle. No drug related serious adverse events (SAE) were recorded. The three dose arms of the protocol showed equal treatment efficacy. The results fulfill the primary objectives of the study protocol. The complete CRO report will be available at the end of October/beginning of November and will contain all lab results and results from the quality of life questionnaires and are expected to confirm/complete the results.

"- The company is very pleased with the results in view of that CRPC is notoriously treatment resistant, says ceo Anders R Holmberg."

For additional information

Gösta Lundgren - CFO & Investor Relations

DexTech Medical AB

Tel.: +46 (0) 707104788

E-mail: gosta.lundgren@dextechmedical.com

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above on October 4, 2018.

DexTech Medical AB is a Swedish research company that based on its technology platform has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful Phase I / IIa study has been conducted with OsteoDex where the result shows high tolerability with mild side effects and the clear effect of the highest dose group. DexTechs goal is to last after phase II trial license the respective drug candidate. DexTech Medical AB is listed on Spotlight Stock Market.